切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2019, Vol. 15 ›› Issue (02) : 143 -149. doi: 10.3877/cma.j.issn.1673-5250.2019.02.004

所属专题： 文献；

论著

初发过敏性紫癜患儿发病早期肾脏受累危险因素分析
孙小妹1, 曹杨1, 戴亮1, 孙飞扬1, 董丽群1,†()   
  1. 1. 四川大学华西第二医院儿科、出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041
  • 收稿日期:2018-10-30 修回日期:2019-03-15 出版日期:2019-04-01
  • 通信作者: 董丽群

Risk factors of renal involvement in children with primary Henoch-Schönlein purpura in the early stage

Xiaomei Sun1, Yang Cao1, Liang Dai1, Feiyang Sun1, Liqun Dong1,†()   

  1. 1. Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2018-10-30 Revised:2019-03-15 Published:2019-04-01
  • Corresponding author: Liqun Dong
  • About author:
    Corresponding author: Dong Liqun, Email:
  • Supported by:
    Scientific Research Project of Health and Family Planning Commission of Sichuan Province(16P238); Project of Pediatric Clinical Medical Research Center of Sichuan Province(2017-46-4); the Forth Baili Scientific Research Project of Chinese Journal of Pediatrics(B2016-C-3); Clinical Medical Research Project of West China Second University Hospital, Sichuan University(K012)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙小妹, 曹杨, 戴亮, 孙飞扬, 董丽群. 初发过敏性紫癜患儿发病早期肾脏受累危险因素分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2019, 15(02): 143-149.

Xiaomei Sun, Yang Cao, Liang Dai, Feiyang Sun, Liqun Dong. Risk factors of renal involvement in children with primary Henoch-Schönlein purpura in the early stage[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2019, 15(02): 143-149.

目的

探讨初发过敏性紫癜(HSP)患儿发病早期肾脏受累的危险因素，为合并肾脏受累危险因素的HSP患儿的临床早期干预提供参考。

方法

选择2011年1月至2015年12月，于四川大学华西第二医院儿科接受住院治疗的1 402例初发HSP患儿为研究对象。根据HSP患儿发病早期是否合并肾脏受累，将其分为肾脏受累组(n＝423)与对照组(n＝979，肾脏未受累)。采用回顾性分析方法，收集所有患儿的临床病例资料。2组患儿性别、发病年龄、居住地区、发病季节、发病至确诊时间的构成比，发病早期皮疹、胃肠道症状、关节肿痛、肾脏受累、血管神经性水肿、神经系统受累发生率等比较，采用χ2检验。采用多因素非条件logistic回归分析，评估HSP患儿发病早期肾脏受累的独立危险因素。本研究遵循的程序符合2013年修订的《世界医学协会赫尔辛基宣言》要求，并与所有受试儿监护人签署临床研究知情同意书。

结果

①本研究1 402例患儿中，发病早期合并肾脏受累为423例(30.17%)，合并胃肠道症状为937例(66.84%)，合并关节肿痛症状为609例(43.33%)，合并血管神经性水肿为352例(25.11%)，合并神经系统受累为31例(2.21%)，所有患儿合并皮疹。②发病早期肾脏受累影响因素的单因素分析结果显示，2组HSP患儿的发病年龄、发病季节、发病至确诊时间的构成比比较，差异均有统计学意义(χ2＝53.682，P<0.001；χ2＝11.990，P＝0.007；χ2＝14.635，P<0.001)。肾脏受累组患儿居住于农村、无关节肿痛症状、合并血管神经性水肿所占比例，均显著高于对照组，并且差异均有统计学意义(χ2＝10.032，P＝0.002；χ2＝6.514，P＝0.011；χ2＝6.362，P＝0.012)。③多因素非条件logistic回归分析结果显示，HSP患儿的发病年龄为≥5～7岁(OR＝2.23，95%CI：1.42～3.51，P<0.001)，≥7～9岁(OR＝2.38，95%CI：1.51～3.76，P<0.001)，≥9岁(OR＝4.11，95%CI：2.65～6.36，P<0.001)，以及于秋季发病(OR＝1.61，95%CI：1.09～2.37，P＝0.014)与冬季发病(OR＝1.79，95%CI：1.09～2.37，P＝0.001)，发病至确诊时间≥8 d(OR＝1.59，95%CI：1.17～2.17，P＝0.004)，居住于农村(OR＝1.37，95%CI：1.07～1.76，P＝0.012)及合并血管神经性水肿(OR＝1.74，95%CI：1.32～2.31，P<0.001)，均为HSP患儿发病早期肾脏受累的独立危险因素；而合并关节肿痛(OR＝0.77，95%CI：0.60～0.99，P＝0.038)，则为HSP患儿发病早期肾脏受累的独立保护因素。

结论

本研究第一次提出合并血管神经性水肿，是初发HSP患儿发病早期肾脏受累的独立危险因素。HSP患儿发病年龄≥5岁、于秋季或者冬季发病、发病至确诊时间≥8 d、居住于农村等，亦均为该病患儿发病早期肾脏受累的独立危险因素。

关键词: 紫癜，过敏性, 危险因素, 血管性水肿, 肾脏受累, 发病早期, 发病年龄, 并发症, 儿童
Objective

To explore the risk factors of renal involvement in children with primary Henoch-Sch?nlein purpura (HSP) in the early stage, and provide clinical references for early intervention of HSP these children with risk factors of renal involvement.

Methods

A total of 1 402 children with primary HSP who hospitalized in Department of Pediatrics, West China Second University Hospital, Sichuan University from January 2011 to December 2015 were included in this study. According to whether combined with renal involvement or not in the early stage of HSP, these children were divided into the renal involvement group (n=423) and control group (n=979, without renal involvement). Their demographic data and clinical manifestation were collected by retrospective method. Constituent ratios of gender, age of onset, residential area, season of onset and duration from symptoms onset to diagnosis, and incidences of skin rash, gastrointestinal symptoms, joint swelling and pain, renal involvement, angioneurotic edema, and nervous system involvement in the early stage were compared between two groups by chi-square test. Multivariate unconditional logistic regression analysis was used to assess the risk factors of renal involvement in children with HSP in the early stage. This study was in line with the World Medical Association Declaration of Helsinki revised in 2013. The guardians of all children signed the clinical research informed consents.

Results

①Among the 1 402 children with HSP, 423 cases (30.17%) occurred renal involvement in the early stage of onset, 937 cases (66.84%) with gastrointestinal symptoms, 609 cases (43.33%) with joint swelling and pain, 352 cases (25.11%) with angioneurotic edema, 31 cases (2.21%) with nervous system involvement, and all cases (100%) with skin rash. ②Univariate analysis of the influencing factors of renal involvement in the early stage of HSP showed that there were statistically significant differences between two groups in constituent ratios of age of onset, season of onset, and duration from symptoms onset to diagnosis (χ2=53.682, P<0.001; χ2=11.990, P=0.007; χ2=14.635, P<0.001). And the proportions of children lived in rural areas, without joint swelling or pain and with angioneurotic edema in renal involvement group all were statistically higher than those in control group, and all the differences were statistically significant (χ2=10.032, P=0.002; χ2=6.514, P=0.011; χ2=6.362, P=0.012). ③Multivariate unconditional logistic regression analysis results showed that the onset age of HSP≥5 years old (≥5-7 years old, OR=2.23, 95%CI: 1.42-3.51, P<0.001; ≥7-9 years old, OR=2.38, 95%CI: 1.51-3.76, P<0.001; ≥9 years old, OR=4.11, 95%CI: 2.65-6.36, P<0.001), onset in the autumn (OR=1.61, 95%CI: 1.09-2.37, P=0.014) and winter (OR=1.79, 95%CI: 1.09-2.37, P=0.001), the duration from symptoms onset to diagnosis ≥8 d (OR=1.59, 95%CI: 1.17-2.17, P=0.004), living in rural areas (OR=1.37, 95%CI: 1.07-1.76, P=0.012) and combined with angioneurotic edema (OR=1.74, 95%CI: 1.32-2.31, P<0.001) were independent risk factors for renal involvement in children with HSP in the early stage. While combined with joint swelling and pain (OR=0.77, 95%CI: 0.60-0.99, P=0.038) was independent protective factors for renal involvement in children with HSP in the early stage.

Conclusions

Results in this study first show that HSP children combined with angioneurotic edema have high risk of renal involvement in the early stage of HSP and reconfirm that onset age of HSP ≥5 years old, onset in autumn or winter, duration from symptoms onset to diagnosis ≥8 d, and residence in rural areas all are the independent risk factors for renal involvements in children with primary HSP in the early stage.

Key words: Purpura, Schoenlein-Henoch, Risk factors, Angioedema, Renal involvement, Early stage of onset, Age of onset, Complications, Child
表1 1 402例过敏性紫癜患儿发病早期的临床资料分析[例数(%)]
临床资料 构成比/发生率 临床资料 构成比/发生率
性别 ? 发病季节 ?
? 男 746(53.21) ? 春季 278(19.83)
? 女 656(46.79) ? 夏季 254(18.12)
发病年龄(岁) ? ? 秋季 325(23.18)
? <5 213(15.19) ? 冬季 545(38.87)
? ≥5～7 391(27.89) 皮疹 1 402(100.00)
? ≥7～9 342(24.39) ? 轻度 976(69.61)
? ≥9 456(32.53) ? 重度 426(30.39)
居住地区 ? 胃肠道症状 937(66.83)
? 农村 630(44.94) 关节肿痛 609(43.44)
? 城市 772(55.06) 肾脏受累 423(30.17)
发病至确诊时间(d) ? 血管神经性水肿 352(25.11)
? ≤3 777(55.42) 神经系统受累 31(2.21)
? >3～8 352(25.11) ? ? ?
? ≥8 273(19.47) ? ? ?
表2 2组过敏性紫癜患儿发病早期肾脏受累影响因素的单因素分析结果[例数(%)]
组别 例数 发病年龄 发病季节 性别
<5岁 ≥5～7岁 ≥7～9岁 ≥9岁 春季 夏季 秋季 冬季 男 女
肾脏受累组 423 32(7.6) 103(24.3) 99(23.4) 189(44.7) 113(26.7) 58(13.7) 67(15.9) 185(43.7) 236(55.8) 187(44.2)
对照组 979 181(18.5) 288(29.4) 243(24.8) 267(27.3) 212(21.7) 220(22.4) 186(19.0) 360(36.7) 510(52.1) 469(47.9)
χ2值 ? 53.682 11.990 1.622
P值 ? <0.001 0.007 0.203
组别 例数 发病至确诊时间 居住地 胃肠道症状 药物或食物变态反应史
≤3 d >3～8 d ≥8 d 农村 城市 无 轻度 严重 是 否
肾脏受累组 423 48(11.3) 89(21.0) 286(67.7) 260(61.5) 163(38.5) 142(33.6) 168(39.7) 113(26.7) 205(48.5) 218(51.5)
对照组 979 190(19.4) 350(35.8) 439(44.8) 512(52.3) 467(47.7) 323(33.0) 432(44.1) 224(22.9) 446(45.6) 533(54.4)
χ2值 ? 14.635 10.032 3.178 1.003
P值 ? <0.001 0.002 0.204 0.316
组别 例数 皮疹 神经系统受累 关节肿痛 血管神经性水肿
轻度 重度 有 无 有 无 有 无
肾脏受累组 423 287(67.8) 136(32.2) 9(2.1) 414(97.9) 162(38.3) 261(61.7) 125(29.5) 298(70.5)
对照组 979 689(70.4) 290(29.6) 22(2.2) 957(97.8) 447(45.7) 532(54.3) 227(23.2) 752(76.8)
χ2值 ? 0.893 0.021 6.514 6.362
P值 ? 0.345 0.885 0.011 0.012
表3 过敏性紫癜患儿发病早期肾脏受累影响因素的多因素非条件logistic回归分析的变量含义及赋值情况
自变量/因变量 变量名 赋值
肾脏受累 y y＝0表示未合并肾脏受累；y＝1表示合并肾脏受累
性别 x1 x1＝1表示男性；x1＝2表示女性
发病年龄 x2 x2＝1表示发病年龄<5岁；x2＝2表示发病年龄为≥5～7岁；x2＝3表示发病年龄为≥7～9岁；x2＝4表示发病年龄≥9岁
发病季节 x3 x3＝1表示于春季发病；x3＝2表示于夏季发病；x3＝3表示于秋季发病；x3＝4表示于冬季发病
居住地 x4 x4＝1表示居住于农村；x4＝2表示居住于城市
药物或食物变态反应史 x5 x5＝0表示无药物或食物变态反应史；x5＝1表示有药物或食物变态反应史
发病至确诊时间 x6 x6＝1表示发病至确诊时间≤3 d；x6＝2表示发病至确诊时间为>3～8 d；x6＝3表示发病至确诊时间≥8 d
皮疹 x7 x7＝0表示轻度皮疹；x7＝1表示重度皮疹
胃肠道症状 x8 x8＝1表示未合并胃肠道症状；x8＝2表示合并轻度胃肠道症状；x8＝3表示合并重度胃肠道症状
关节肿痛 x9 x9＝0表示未合并关节肿痛；x9＝1表示合并关节肿痛
血管神经性水肿 x10 x10＝0表示未合并血管神经性水肿；x10＝1表示合并血管神经性水肿
神经系统受累 x11 x11＝0表示未合并神经系统受累；x11＝1表示合并神经系统受累
表4 过敏性紫癜患儿发病早期肾脏受累影响因素的多因素非条件logistic回归分析结果
影响因素 B SE Wald值 P值 OR值 OR值95%CI
发病年龄(岁) ? ? ? ? ? ?
? ≥5～7 0.802 0.231 12.093 <0.001 2.23 1.42～3.51
? ≥7～9 0.867 0.233 13.836 <0.001 2.38 1.51～3.76
? ≥9 1.413 0.223 40.126 <0.001 4.11 2.65～6.36
女性 －0.172 0.124 1.928 0.165 0.84 0.66～1.07
发病季节 ? ? ? ? ? ?
? 春季 0.207 0.208 0.996 0.318 1.23 0.82～1.85
? 秋季 0.487 0.198 6.072 0.014 1.61 1.09～2.37
? 冬季 0.573 0.180 10.149 0.001 1.79 1.09～2.37
居住于农村 0.316 0.126 6.342 0.012 1.37 1.07～1.76
药物或食物变态反应史 0.239 0.126 3.635 0.057 1.27 0.86～1.12
发病至确诊时间(d) ? ? ? ? ? ?
? >3～8 0.185 0.150 1.521 0.218 1.2 0.90～1.62
? ≥8 0.461 0.158 8.462 0.004 1.59 1.17～2.17
重度皮疹 －0.051 0.135 0.142 0.706 0.95 0.73～1.24
胃肠道症状 ? ? ? ? ? ?
? 轻度 －0.084 0.146 0.331 0.565 0.92 0.69～1.22
? 重度 0.212 0.165 1.642 0.200 1.24 0.89～1.71
关节肿痛 －0.264 0.128 4.286 0.038 0.77 0.60～0.99
血管神经性水肿 0.556 0.143 15.067 <0.001 1.74 1.32～2.31
神经系统受累 －0.139 0.432 0.104 0.747 0.87 0.37～2.03
[1]
Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins[J]. Lancet, 2002, 360(9341): 1197-1202.
[2]
Yang YH, Hung CF, Hsu CR, et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan[J]. Rheumatology, 2005, 44(5): 618-622.
[3]
李克莉，刘大卫，武文娣，等. 中国六个市2007～2009年过敏性紫癜住院病例发病情况分析[J]. 中国疫苗和免疫，2011, 17(2): 128-132.
[4]
Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children[J]. Nat Rrev Nephrol, 2014, 10(10): 563-573.
[5]
吴小川. 儿童过敏性紫癜循证诊治建议解读[J]. 中华儿科杂志，2013, 51(7): 508-511.
[6]
Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children[J]. Arch Dis Child, 2010, 95(11): 877-882.
[7]
Chan H, Tang YL, Lv XH, et al. Risk Factors associated with renal involvement in childhood Henoch-Schönlein purpura: a Meta-analysis[J]. PLoS One, 2016, 11(11): e0167346.
[8]
Sano H, Izumida M, Shimizu H, et al. Risk factors of renal involvement and significant proteinuria in Henoch-Schönlein purpura[J]. Eur J Pediatr, 2002, 161(4): 196-201.
[9]
Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study[J]. Lancet, 2002, 360(9334): 666-670.
[10]
Bogdanović R. Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment[J]. Acta Paediatr, 2009, 98(12): 1882-1889.
[11]
Ozen S, Pistorio A, Iusan SM, et al. EULAR/ PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part Ⅱ：Final classification criteria[J]. Ann Rheum Dis, 2010, 69(5): 798-806.
[12]
Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management[J]. World J Pediatr, 2015, 11(1): 29-34.
[13]
Rostoker G. Schönlein-henoch purpura in children and adults: diagnosis, pathophysiology and management[J]. BioDrugs, 2001, 15(2): 99-138.
[14]
Rigante D, Candelli M, Federico G, et al. Predictive factors of renal involvement or relapsing disease in children with Henoch-Schönlein purpura[J]. Rheumatol Int, 2005, 25(1): 45-48.
[15]
孙小妹，戴亮，孙飞扬，等. 成都地区与川西高原地区过敏性紫癜患儿临床特征比较[J]. 现代预防医学，2018, 45(12): 2274-2276, 2287.
[16]
Zhao YL, Liu ZJ, Bai XM, et al. Obesity increases the risk of renal involvement in children with Henoch-Schonlein purpura[J]. Eur J Pediatr, 2015, 174(10): 1357-1363.
[17]
Shin JI, Park JM, Shin YH, et al. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schönlein purpura[J]. Scand J Rheumatol, 2006, 35(1): 56-60.
[18]
de Almeida JL, Campos LM, Paim LB, et al. Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors[J]. J Pediatr (Rio J), 2007, 83(3): 259-266.
[19]
Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review[J]. Arch Dis Child, 2005, 90(9): 916-920.
[20]
Gupta V, Aggarwal A, Gupta R, et al. Differences between adult and pediatric onset Henoch-Schonlein purpura from North India[J]. Int J Rheum Dis, 2018, 21(1): 292-298.
[21]
Algoet C, Proesmans W. Renal biopsy 2-9 years after Henoch Schönlein purpura[J]. Pediatr Nephrol, 2003, 18(5): 471-473.
[22]
Yang YH, Hung CF, Hsu CR, et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan[J]. Rheumatology (Oxford), 2005, 44(5): 618-622.
[23]
Wang XH, Zhu YM, Gao LQ, et al. Henoch-Schönlein purpura with joint swelling and involvement: analysis of 71 cases[J]. Pediatr Rheumatol Online J, 2016, 14(1): 20.
[24]
Wang K, Sun X, Cao Y, et al. Risk factors for renal involvement and severe kidney disease in 2 731 Chinese children with Henoch-Schönlein purpura: a retrospective study[J]. Medicine (Baltimore), 2018, 97(38): e12520.
[25]
Lee YH, Kim YB, Koo JW, et al. Henoch-Schonlein purpura in children hospitalized at a tertiary hospital during 2004-2015 in Korea: epidemiology and clinical management[J]. Pediatr Gastroenterol Hepatol Nutr, 2016, 19(3): 175-185.
[26]
Mao YY, Yin L, Huang H, et al. Henoch-Schönlein purpura in 535 Chinese children: clinical features and risk factors for renal involvement[J]. J Int Med Res, 2014, 42(4): 1043-1049.
[27]
刘雄彪，汪晓红，刘璐苑，等. 过敏性紫癜伴发血管神经性水肿7例[J]. 中国皮肤性病学杂志，2017, 31(8): 927.
[28]
Duman MA, Duru NS, Çalışkan B, et al. Lumbar swelling as the unusual presentation of Henoch-Schonlein purpura in a child[J]. Balkan Med J, 2016, 33(3): 360-362.
[29]
王佳佩，吴菱，王天波，等. 伴血管神经性水肿的过敏性紫癜患儿预后及治疗[J]. 临床荟萃，2017, 32(1): 68-70.
[1] 陶宏宇, 叶菁菁, 俞劲, 杨秀珍, 钱晶晶, 徐彬, 徐玮泽, 舒强. 右心声学造影在儿童右向左分流相关疾病中的评估价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(10): 959-965.
[2] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[3] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[4] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[5] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[7] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[8] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9] 康婵娟, 张海涛, 翟静洁. 胰管支架置入术治疗急性胆源性胰腺炎的效果及对患者肝功能、炎症因子水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 667-670.
[10] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[11] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[12] 刘柏隆, 周祥福. 女性尿失禁吊带手术并发症处理的经验分享[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 127-127.
[13] 嵇振岭, 陈杰, 唐健雄. 重视复杂腹壁疝手术并发症的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 601-606.
[14] 江志鹏, 钟克力, 陈双. 复杂腹壁疝手术后腹腔高压与腹腔间室综合征的预防和处理[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 612-615.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号